Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
SPONSORED CONTENTAs Simple As One DoseDefends dogs against ticks and fleas and also protects against heartworm disease, roundworms, hookworms, tapeworms and New World screwworm. + Learn More
